Verition Fund Management
HZNP

Verition Fund Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Verition Fund Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-81,200
Closed -$8.35M – 2833
2023
Q2 		$8.35M Buy
+81,200
New +$8.57M 0.11% 249
2023
Q1 		– Sell
-2,000
Closed -$228K – 2783
2022
Q4 		$228K Sell
2,000
-3,900
-66% -$324K ﹤0.01% 1670
2022
Q3 		$365K Buy
+5,900
New +$412K ﹤0.01% 2100
2022
Q2 		– Sell
-6,500
Closed -$684K – 3340
2022
Q1 		$684K Hold
6,500
– – 0.01% 1714
2021
Q4 		$700K Buy
+6,500
New +$709K 0.01% 1513

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Verition Fund Management's HZNP Position: Q4 2023 in Review

Verition Fund Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 367,671 shares — an estimated $42.5M sold.

Verition Fund Management first reported a position in HZNP in Q4 2013 and held it in 12 quarters. The position peaked at $96.6M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Verition Fund Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Verition Fund Management sold 367,671 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $42.5M.
  • Verition Fund Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 12 quarters.
  • Verition Fund Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $96.6M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.